Context Therapeutics Inc. (NASDAQ:CNTX) Stock Holdings Lowered by Ally Bridge Group NY LLC

Ally Bridge Group NY LLC cut its position in Context Therapeutics Inc. (NASDAQ:CNTX) by 6.8% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,757,524 shares of the company’s stock after selling 128,708 shares during the quarter. Context Therapeutics comprises 1.8% of Ally Bridge Group NY LLC’s holdings, making the stock its 28th biggest position. Ally Bridge Group NY LLC’s holdings in Context Therapeutics were worth $3,445,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of CNTX. Renaissance Technologies LLC increased its stake in shares of Context Therapeutics by 63.4% in the second quarter. Renaissance Technologies LLC now owns 65,200 shares of the company’s stock valued at $131,000 after purchasing an additional 25,300 shares during the period. Opaleye Management Inc. grew its holdings in Context Therapeutics by 13.7% in the 1st quarter. Opaleye Management Inc. now owns 1,108,357 shares of the company’s stock worth $1,530,000 after buying an additional 133,357 shares in the last quarter. Affinity Asset Advisors LLC increased its position in Context Therapeutics by 392.4% in the 2nd quarter. Affinity Asset Advisors LLC now owns 1,619,140 shares of the company’s stock valued at $3,246,000 after acquiring an additional 1,290,323 shares during the period. Nantahala Capital Management LLC acquired a new stake in Context Therapeutics in the 2nd quarter valued at approximately $3,881,000. Finally, Driehaus Capital Management LLC bought a new stake in Context Therapeutics during the 2nd quarter valued at $4,527,000. 14.03% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

CNTX has been the topic of a number of research analyst reports. D. Boral Capital initiated coverage on Context Therapeutics in a report on Monday. They set a “buy” rating and a $9.00 price target on the stock. HC Wainwright reiterated a “buy” rating and issued a $6.00 target price on shares of Context Therapeutics in a research report on Monday, September 23rd. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $6.80.

Context Therapeutics Stock Up 2.0 %

Shares of Context Therapeutics stock opened at $1.50 on Thursday. The business has a fifty day simple moving average of $1.96 and a 200-day simple moving average of $2.07. Context Therapeutics Inc. has a fifty-two week low of $0.77 and a fifty-two week high of $2.75. The firm has a market cap of $112.50 million, a price-to-earnings ratio of -1.65 and a beta of 2.25.

Context Therapeutics (NASDAQ:CNTX) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.11). Analysts anticipate that Context Therapeutics Inc. will post -0.51 earnings per share for the current fiscal year.

Context Therapeutics Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.